Ann: Publication of Invex IIH Phase II Pressure Trial Results, page-8

You are spot on, the other thing to keep in mind is that any second indication is an identical API to out primary indication and it will be targeting the same MOA.

Assuming we get a positive read out on EVOLVE and they are still looking to sell up, I would think somebody looking at our second indication (assuming it is TBI) would see it is the same API, targeting the same MOA, with a very well understood safety profile and is about to go in to a Phase II for TBI. Clearly that has some value, I would think even in a tough market, at a minimum that would be wroth at least the current market cap in and of itself.